At the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland, Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ gives an overview of a session on what the most appropriate approach to treating patients with relapsed myeloma is. One of the key messages is the importance of using multiple drugs for treating multiple clones of the disease, according to Dr Stewart. He further discusses the combination of lenalidomide and dexamethasone as a backbone of carfilzomib, ixazomib and elotuzumab. According to Dr Stewart, randomized trials show that the combination of lenalidomide and dexamethasone and a novel agent, show improved progression-free survival (PFS) and improved overall survival (OS).
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates